Epigenomics is a molecular diagnostics company focused on developing innovative screening tests for cancer. Our lead product, Epi proColon, is the first and only FDA-approved blood-based test for colorectal cancer.  In the US today, 1 in 3, or 23 million eligible people, are not screened for colorectal cancer.  Epi proColon provides a convenient blood-based option to address this non-screened population.